Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
about
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsChimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challengesImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationT cell immune abnormalities in immune thrombocytopenia.Engineered T cells for cancer treatmentβ-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Construction and evaluation of a novel humanized HER2-specific chimeric receptorICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion.A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastomaMaking Better Chimeric Antigen Receptors for Adoptive T-cell TherapyToxicities of chimeric antigen receptor T cells: recognition and management.Adoptive immunotherapy for cancer.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Glioblastoma stem cells and stem cell-targeting immunotherapies.ErbB-targeted CAR T-cell immunotherapy of cancer.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Immune and viral therapies for malignant primary brain tumors.Driving better and safer HER2-specific CARs for cancer therapy.Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy.Practical considerations for chimeric antigen receptor design and delivery.Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.The development of CAR design for tumor CAR-T cell therapy.The Potential of CAR T Cell Therapy in Pancreatic CancerCART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
P2860
Q26795540-7DA58410-025C-44D7-A351-676385D188B1Q27025300-CB12F934-C051-4EF7-BA2E-B317AA39D611Q28068378-00A6271A-49F0-45F3-85A2-B416EBD51CAAQ33417942-E5C1C370-BC0A-4807-9615-5AA7B2A27F05Q33578792-5DBB18AA-92FB-4502-B653-02B3503B78F1Q33578997-223EACBD-932F-4246-91C2-8C1E5C359E3DQ33795137-3A389600-F177-437F-A7E4-F379A187F5BFQ33892746-428A0802-EBA7-429D-A55C-3590BB16625EQ34047847-86A9FD00-9EE2-4A19-BC4F-9DA53457F9F1Q34256494-E2339DAA-DD86-45DB-AF1B-7CCB45B11C6DQ35879993-9CE7F6EF-7722-4A9B-8CE3-0E8B83FC6C59Q36356392-14905305-A333-4752-9BA6-BC2F1FC28809Q36474226-C59F0BAD-48ED-4E65-83F4-40356299EFDCQ36830759-9F457989-3AA7-40A3-8F5B-D28A73556535Q37058104-A63F6EAF-0CA7-4291-A9B9-167B58793E4BQ38170496-C8E6FF01-DA5B-4BCA-B2DB-5070BBF5AA63Q38227889-5AB15481-2B9B-4C9B-AD97-9991E1B67DB2Q38355702-DA728C71-C32E-4A81-AA15-0339FCAC8CEFQ38389298-5D1A68FE-BAFB-4A64-9A92-5E16C2DB089DQ38786626-566D160B-B3C8-475C-AF96-955885DCEFF4Q38830813-517173DA-9698-4BEE-B4F9-41E429B812AFQ38913549-518A0D4A-D59C-4DAD-896D-C8C4694E3035Q38951943-08EDB759-45F4-4C8C-B143-EF6715EDB8EBQ39168899-A4196A8E-A0F4-4C5F-B561-51F011108F0FQ41835996-0395469F-D6FB-481D-BDEA-AA94F34AB023Q42246628-B8CE3C83-85F3-4879-B12A-F871680A9BA3Q45868559-90AA4EB9-347C-4B9B-9DFE-26DF9F72D1D9Q47142244-2E7BC948-FCFD-440B-988A-8B8FAB14CBB5Q47812178-CF175CCB-F8F8-4BF6-81E4-F99176997704Q48175410-4EFFBDE9-BE58-40C2-9963-4EDA577AB1E1Q49280922-C76482E2-429F-4377-91F6-3F5050F34254Q52641562-D5C8AF2F-773C-4132-A572-077A65893332Q57492021-73633625-B91E-4FC8-94F2-B8793EF65E9FQ58606449-0F6B40CC-DCCB-4F39-9D08-70A5CCC4218C
P2860
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Chimeric antigen receptor cont ...... st EGFRvIII expressing glioma.
@en
type
label
Chimeric antigen receptor cont ...... st EGFRvIII expressing glioma.
@en
prefLabel
Chimeric antigen receptor cont ...... st EGFRvIII expressing glioma.
@en
P2093
P2860
P356
P1476
Chimeric antigen receptor cont ...... st EGFRvIII expressing glioma.
@en
P2093
Albert J Wong
Chan-Juan Shen
Ethan Q Han
Li-Ming Zhao
Puja Gupta
Shuang-Yin Han
Ying-Ying Zhao
P2860
P2888
P356
10.1186/1756-8722-6-33
P577
2013-05-09T00:00:00Z
P5875
P6179
1048842827